Free Trial
→ Trump Orders 'National Digital Asset Stockpile' (From Crypto 101 Media) (Ad) Buy SMMT Stock  Free SMMT Stock Alerts

Summit Therapeutics (SMMT) Financials

Summit Therapeutics logo
$26.13 +2.89 (+12.44%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Summit Therapeutics

Annual Income Statements for Summit Therapeutics

This table shows Summit Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -38 -27 -29 11 -53 -89 -79 -615 -221
Consolidated Net Income / (Loss)		 -29 -27 -29 11 -53 -89 -79 -615 -221
Net Income / (Loss) Continuing Operations		 -38 -27 -29 11 -53 -89 -79 -615 -221
Total Pre-Tax Income 		-33 -33 -34 9.08 -53 -89 -76 -626 -235
Total Operating Income		 -29 -31 -32 5.39 -53 -86 -72 -610 -226
Total Gross Profit		 -29 -31 -37 57 0.86 1.81 0.71 0.00 0.00
Total Revenue		 0.00 3.02 26 57 0.86 1.81 0.71 0.00 0.00
Operating Revenue		 0.00 3.02 26 57 0.86 1.81 0.71 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 29 34 58 52 54 88 73 610 226
Selling, General & Admin Expense		 6.89 10 17 17 19 24 27 30 61
Research & Development Expense		 24 24 41 52 53 85 52 580 166
Other Operating Expenses / (Income)		 -1.85 - - -23 -19 -21 -14 -1.00 -0.31
Impairment Charge		 - 0.00 0.00 5.29 0.86 0.00 8.47 0.00 0.00
Total Other Income / (Expense), net		 -4.11 -1.09 -1.69 3.69 0.28 -2.42 -4.40 -16 -8.69
Interest Expense		 4.16 - - - - - 4.40 16 8.69
Other Gains / (Losses), net		 - - - - - - -2.29 11 13
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - - 0.00 0.42 0.00
Basic Earnings per Share		 - - - $0.63 ($0.76) ($0.67) ($0.41) ($0.99) ($0.31)
Weighted Average Basic Shares Outstanding		 - - 73.56M 17.14M 69.52M 131.71M 193.34M 619.65M 718.54M
Diluted Earnings per Share		 - - - $0.63 ($0.76) ($0.67) ($0.41) ($0.99) ($0.31)
Weighted Average Diluted Shares Outstanding		 - - 73.56M 17.23M 69.52M 131.71M 193.34M 619.65M 718.54M
Weighted Average Basic & Diluted Shares Outstanding		 - - 73.56M 160.39M 82.92M 98.12M 697.69M 701.70M 737.68M

Quarterly Income Statements for Summit Therapeutics

This table shows Summit Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -21 -19 -543 -16 -21 -36 -43 -60 -56 -61
Consolidated Net Income / (Loss)		 -21 -19 -542 -15 -21 -37 -43 -60 -56 -61
Net Income / (Loss) Continuing Operations		 -21 -19 -542 -15 -21 -37 -43 -60 -56 -61
Total Pre-Tax Income 		-21 -16 -542 -15 -21 -48 -43 -60 -56 -75
Total Operating Income		 -17 -20 -537 -16 -20 -36 -42 -60 -58 -66
Total Operating Expenses		 17 20 537 16 20 36 42 60 58 66
Selling, General & Admin Expense		 5.57 7.58 6.94 6.32 5.43 12 12 14 20 14
Research & Development Expense		 17 5.39 531 9.45 15 25 31 46 38 51
Other Operating Expenses / (Income)		 -5.46 -1.13 -0.58 0.03 -0.27 -0.18 -0.21 -0.16 0.26 -0.21
Total Other Income / (Expense), net		 -4.45 4.12 -5.22 1.08 -0.78 -12 -1.08 -0.77 2.12 -8.96
Basic Earnings per Share		 ($0.10) ($0.04) ($1.43) ($0.02) ($0.03) $0.49 ($0.06) ($0.09) ($0.08) ($0.08)
Weighted Average Basic Shares Outstanding		 208.91M 193.34M 378.16M 697.69M 697.74M 619.65M 701.79M 707.90M 726.66M 718.54M
Diluted Earnings per Share		 ($0.10) ($0.04) ($1.43) ($0.02) ($0.03) $0.49 ($0.06) ($0.09) ($0.08) ($0.08)
Weighted Average Diluted Shares Outstanding		 208.91M 193.34M 378.16M 697.69M 697.74M 619.65M 701.79M 707.90M 726.66M 718.54M
Weighted Average Basic & Diluted Shares Outstanding		 201.32M 697.69M 697.69M 697.69M 700.84M 701.70M 701.98M 724.54M 737.45M 737.68M

Annual Cash Flow Statements for Summit Therapeutics

This table details how cash moves in and out of Summit Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 7.10 16 -8.59 9.07 2.58 5.37 577 -578 34
Net Cash From Operating Activities		 -25 15 -21 -35 -48 -73 -42 -77 -142
Net Cash From Continuing Operating Activities		 -26 15 -20 -35 -48 -73 -42 -77 -142
Net Income / (Loss) Continuing Operations		 -33 -33 -34 11 -53 -89 -79 -615 -221
Consolidated Net Income / (Loss)		 -33 -33 -34 11 -53 -89 -79 -615 -221
Depreciation Expense		 0.05 0.06 0.42 0.41 0.30 0.33 0.35 0.20 0.09
Amortization Expense		 - - - 1.10 1.70 2.13 0.91 -1.92 -2.58
Non-Cash Adjustments To Reconcile Net Income		 5.54 3.74 2.28 7.86 2.07 14 26 540 66
Changes in Operating Assets and Liabilities, net		 1.53 44 12 -55 0.52 -0.07 9.72 -0.16 16
Net Cash From Investing Activities		 -0.05 -0.10 -7.48 -0.33 -0.42 -0.31 -0.62 -588 -205
Net Cash From Continuing Investing Activities		 -0.05 -0.10 -0.67 -0.33 -0.42 -0.31 -0.62 -588 -205
Purchase of Property, Plant & Equipment		 -0.10 -0.11 -0.68 -0.16 -0.42 -0.31 -0.62 -0.13 -0.14
Purchase of Investments		 - - - - - - 0.00 -321 -680
Sale of Property, Plant & Equipment		 - - - - - - 0.00 0.23 0.00
Sale and/or Maturity of Investments		 - - - - - - 0.00 208 490
Other Investing Activities, net		 0.04 0.01 0.02 -0.17 - - - -475 -15
Net Cash From Financing Activities		 32 0.52 20 45 51 78 620 87 381
Net Cash From Continuing Financing Activities		 32 0.52 20 45 51 78 620 87 381
Repayment of Debt		 - - -0.18 - 0.00 -110 -25 -25 -100
Repurchase of Common Equity		 -6.04 0.00 -2.04 -1.71 -0.05 -0.12 -0.11 -0.62 0.00
Issuance of Debt		 0.00 0.03 - - 0.00 110 545 0.00 0.00
Issuance of Common Equity		 38 0.00 21 46 50 75 100 111 481
Other Financing Activities, net		 0.32 0.49 0.57 0.13 0.60 3.09 0.00 1.20 0.60
Cash Interest Paid		 - - - - 0.00 0.09 0.43 11 8.81
Cash Income Taxes Paid		 - - - 0.07 -0.07 - 0.00 0.05 0.00

Quarterly Cash Flow Statements for Summit Therapeutics

This table details how cash moves in and out of Summit Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 65 527 -578 -29 -18 47 -9.81 -33 65 11
Net Cash From Operating Activities		 -8.56 5.19 -13 -29 -15 -19 -30 -33 -30 -49
Net Cash From Continuing Operating Activities		 -8.56 5.01 -13 -29 -15 -19 -30 -33 -30 -49
Net Income / (Loss) Continuing Operations		 -21 -19 -542 -15 -21 -37 -43 -60 -56 -61
Consolidated Net Income / (Loss)		 -21 -19 -542 -15 -21 -37 -43 -60 -56 -61
Depreciation Expense		 0.09 0.09 0.09 0.05 0.03 0.03 0.03 0.02 0.02 0.02
Amortization Expense		 0.62 -0.74 0.00 -2.90 1.19 -0.21 -0.40 -1.61 -2.92 2.35
Non-Cash Adjustments To Reconcile Net Income		 4.62 12 529 1.41 0.97 8.34 9.42 26 20 11
Changes in Operating Assets and Liabilities, net		 7.50 13 -0.16 -13 4.19 8.95 4.29 3.16 8.93 -0.73
Net Cash From Investing Activities		 0.02 0.01 -645 0.21 -3.49 61 20 -200 -109 83
Net Cash From Continuing Investing Activities		 0.02 0.01 -645 0.21 -3.49 61 20 -200 -109 83
Purchase of Property, Plant & Equipment		 0.02 0.01 -0.05 -0.02 -0.05 -0.00 -0.00 -0.06 -0.06 -0.01
Purchase of Investments		 - - -170 -38 -113 0.00 -93 -270 -168 -149
Sale and/or Maturity of Investments		 - - 0.00 38 109 61 113 70 74 233
Net Cash From Financing Activities		 75 520 80 -0.08 0.23 6.25 0.49 200 204 -24
Net Cash From Continuing Financing Activities		 75 520 80 -0.08 0.23 6.25 0.49 200 204 -24
Repayment of Debt		 -25 -0.04 -25 - - - 0.00 - -76 -25
Issuance of Common Equity		 100 0.10 105 - -0.39 5.67 0.49 200 280 0.39
Other Financing Activities, net		 - - - - - 1.20 - - - 0.50
Cash Interest Paid		 0.43 - 1.31 3.49 2.92 2.94 1.50 - - 7.31

Annual Balance Sheets for Summit Therapeutics

This table presents Summit Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 48 77 96 102 113 664 203 436
Total Current Assets		 42 51 80 88 97 657 190 424
Cash & Equivalents		 36 29 64 66 72 349 71 105
Restricted Cash		 - - - - 0.00 300 0.00 0.33
Short-Term Investments		 - - - - - 0.00 115 307
Prepaid Expenses		 - - 8.76 9.55 7.16 1.50 2.62 11
Other Current Assets		 - - 1.40 11 17 6.25 0.85 0.56
Plant, Property, & Equipment, net		 94 1.15 0.52 0.73 0.69 0.91 0.20 0.25
Total Noncurrent Assets		 5.23 25 16 14 15 6.55 13 12
Goodwill		 0.84 3.53 1.96 2.03 2.01 1.80 1.89 1.86
Other Noncurrent Operating Assets		 - - 1.02 0.55 2.96 4.75 11 9.69
Total Liabilities & Shareholders' Equity		 141 73 96 102 113 664 203 436
Total Liabilities		 52 82 17 23 30 538 125 47
Total Current Liabilities		 14 32 14 20 26 39 20 42
Accounts Payable		 5.04 13 4.47 6.14 4.37 0.36 2.67 4.64
Accrued Expenses		 - - 5.74 3.28 7.20 11 8.78 20
Current Employee Benefit Liabilities		 - - - 0.98 4.13 5.64 5.43 12
Other Current Liabilities		 - 20 0.84 1.12 1.99 2.35 3.53 5.56
Total Noncurrent Liabilities		 97 49 3.62 3.16 4.47 499 105 5.08
Long-Term Debt		 - - - - 0.00 495 100 0.00
Other Noncurrent Operating Liabilities		 66 41 3.13 2.59 4.47 4.19 4.85 5.08
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 30 -4.54 79 79 83 127 78 389
Total Preferred & Common Equity		 30 -4.54 79 79 83 127 78 389
Preferred Stock		 - 86 - - 0.00 0.00 0.00 0.00
Total Common Equity		 30 -90 79 79 83 127 78 389
Common Stock		 0.78 1.05 242 294 385 507 1,073 1,606
Retained Earnings		 - -134 -158 -211 -300 -378 -993 -1,215
Accumulated Other Comprehensive Income / (Loss)		 - - -4.76 -3.79 -2.20 -1.89 -2.45 -2.29

Quarterly Balance Sheets for Summit Therapeutics

This table presents Summit Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 155 255 237 218 177 342 503
Total Current Assets		 137 248 228 205 163 329 490
Cash & Equivalents		 122 71 42 24 61 28 94
Restricted Cash		 - 0.00 0.00 0.00 0.32 0.32 0.32
Short-Term Investments		 - 171 173 175 95 297 393
Prepaid Expenses		 1.62 1.19 6.09 5.07 5.32 2.05 2.41
Other Current Assets		 13 4.91 6.39 0.93 0.95 0.95 0.66
Plant, Property, & Equipment, net		 0.93 0.41 0.23 0.23 0.18 0.22 0.27
Total Noncurrent Assets		 17 6.46 9.65 13 13 13 12
Goodwill		 1.66 1.84 1.88 1.81 1.88 1.88 1.99
Other Noncurrent Operating Assets		 7.67 4.08 7.76 11 11 11 10
Total Liabilities & Shareholders' Equity		 155 255 237 218 177 342 503
Total Liabilities		 22 121 118 119 133 147 65
Total Current Liabilities		 17 17 12 114 23 140 59
Short-Term Debt		 - 0.00 0.00 100 - 100 25
Accounts Payable		 1.43 0.71 0.99 3.31 6.37 3.34 3.25
Accrued Expenses		 11 12 3.87 3.65 6.55 27 18
Current Employee Benefit Liabilities		 2.51 2.42 3.53 3.51 6.03 4.88 7.96
Other Current Liabilities		 1.60 2.01 3.55 3.26 4.49 4.49 4.82
Total Noncurrent Liabilities		 5.40 104 106 5.36 109 6.61 5.92
Long-Term Debt		 - 100 100 0.00 100 0.00 0.00
Other Noncurrent Operating Liabilities		 5.40 3.97 5.84 5.36 9.13 6.61 5.92
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 133 133 120 99 44 195 438
Total Preferred & Common Equity		 133 133 120 99 44 195 438
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 133 133 120 99 44 195 438
Common Stock		 496 1,056 1,057 1,058 1,083 1,295 1,594
Retained Earnings		 -359 -921 -935 -957 -1,037 -1,097 -1,153
Accumulated Other Comprehensive Income / (Loss)		 -3.22 -1.40 -2.44 -2.32 -2.45 -2.50 -2.31

Annual Metrics and Ratios for Summit Therapeutics

This table displays calculated financial ratios and metrics derived from Summit Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 759.29% 120.15% -98.49% 110.35% -61.03% -100.00% 0.00%
EBITDA Growth		 0.00% -10.81% -3.75% 131.43% -580.62% -69.22% 17.78% -763.21% 62.63%
EBIT Growth		 0.00% -10.81% -4.84% 126.62% -682.52% -67.46% 18.64% -745.69% 62.93%
NOPAT Growth		 0.00% -7.10% -3.10% 128.41% -677.41% -62.03% 16.36% -745.69% 62.93%
Net Income Growth		 0.00% 6.92% -6.28% 137.80% -584.84% -68.13% 11.08% -680.54% 64.01%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -220.63% 11.84% 38.81% -141.46% 68.69%
Operating Cash Flow Growth		 0.00% 161.97% -234.94% -69.28% -37.04% -50.87% 42.71% -84.60% -85.13%
Free Cash Flow Firm Growth		 0.00% 0.00% 104.69% -4,893.20% 6.24% -67.27% 46.71% -1,259.39% 66.46%
Invested Capital Growth		 0.00% 0.00% -440.78% 152.51% -13.82% -11.84% -166.50% -11.87% -179.84%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 3.79% -26.26% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -24.39% 5.88% -2.81% -14.32%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -23.58% 7.38% -2.68% -14.91%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -20.21% 7.38% -2.68% -14.96%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -18.07% 9.08% -2.90% -12.53%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 22.09% -13.89% 34.87% -219.23%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 21.62% -1.69% 25.68% -47.30% -25.88%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 28.34% -5.21% -27.09%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -47.88% -167.78% -2,070.05% 3.52%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% -1,042.49% -142.07% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 0.00% -1,076.30% -129.95% 18.55% -5,919.42% -4,762.13% -10,046.24% 0.00% 0.00%
Operating Margin		 0.00% -1,042.16% -125.04% 9.44% -6,185.23% -4,764.29% -10,225.39% 0.00% 0.00%
EBIT Margin		 0.00% -1,078.31% -131.57% 15.91% -6,152.33% -4,897.84% -10,225.39% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -896.43% -110.87% 19.04% -6,127.56% -4,897.84% -11,174.75% 0.00% 0.00%
Tax Burden Percent		 86.82% 83.13% 84.27% 119.66% 99.60% 100.00% 103.00% 98.21% 94.30%
Interest Burden Percent		 114.00% 100.00% 100.00% 100.00% 100.00% 100.00% 106.11% 102.70% 103.84%
Effective Tax Rate		 0.00% 0.00% 0.00% -19.66% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -264.44% -491.91% -2,621.42% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -240.68% -451.00% -2,593.94% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 197.86% 383.02% 2,546.37% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -89.59% -224.14% 29.25% -66.57% -108.89% -75.05% -601.85% -94.90%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -247.81% -249.59% -479.33% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -68.39% -54.79% 10.49% -53.24% -82.09% -18.54% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -56.86% -46.17% 12.55% -53.03% -82.09% -20.26% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -89.59% 526.52% -4.56% -66.57% -108.89% -75.05% -601.85% -94.90%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -89.59% 633.10% 13.78% -66.32% -106.39% -62.20% -791.49% -56.93%
Net Operating Profit after Tax (NOPAT)		 -21 -22 -23 6.45 -37 -60 -50 -427 -158
NOPAT Margin		 0.00% -729.51% -87.53% 11.30% -4,329.66% -3,335.00% -7,157.77% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -28.36% -20.25% 10.05% -23.76% -40.91% -27.48% -170.65% -25.30%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -7.87% -240.17% -40.69%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 347.19% 65.65% 29.80% 2,236.28% 1,305.20% 3,793.33% 0.00% 0.00%
R&D to Revenue		 0.00% 794.97% 159.39% 91.09% 6,194.65% 4,718.19% 7,375.74% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 1,142.16% 225.04% 90.56% 6,285.23% 4,864.29% 10,325.39% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -29 -33 -34 9.08 -53 -89 -72 -610 -226
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -32 -34 11 -51 -86 -71 -611 -228
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 1.24 4.87 3.16 3.29 23.54 33.85
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 1.53 5.87 3.71 3.34 24.13 34.01
Price to Revenue (P/Rev)		 0.00 0.00 0.00 1.71 449.56 145.30 591.52 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 9.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 11.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 2.25 24.56 16.62 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.60 372.33 105.62 401.03 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 3.22 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 3.75 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 5.28 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 4.06 1.29 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 3.90 1.29 0.00
Financial Leverage		 0.00 -1.18 -2.33 -1.18 -0.82 -0.85 -0.98 -1.08 -1.07
Leverage Ratio		 0.00 1.58 4.85 2.33 1.26 1.33 3.70 4.24 1.37
Compound Leverage Factor		 0.00 1.58 4.85 2.33 1.26 1.33 3.93 4.36 1.42
Debt to Total Capital		 0.00% 0.00% 0.00% 0.13% 0.00% 0.00% 80.24% 56.28% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.13% 0.00% 0.00% 3.08% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 77.16% 56.28% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% -1,891.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 1,991.87% 99.87% 100.00% 100.00% 19.76% 43.72% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.01 0.00 0.00 -7.26 -0.16 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 -6.02 0.00 0.00 1.90 0.14 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -6.98 -0.16 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.02 0.00 0.00 -10.19 -0.23 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 -9.88 0.00 0.00 2.66 0.20 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -9.80 -0.23 0.00
Altman Z-Score		 0.00 0.00 0.00 2.80 6.28 -0.26 0.43 -7.00 164.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 334.90% 115.60% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 3.06 1.58 5.78 4.41 3.80 16.93 9.30 10.15
Quick Ratio		 0.00 2.67 1.37 4.68 3.36 2.86 9.00 9.13 9.88
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -17 0.78 -37 -35 -59 -31 -426 -143
Operating Cash Flow to CapEx		 -26,033.37% 13,796.55% -3,035.49% -22,360.51% -11,427.79% -23,721.24% -6,663.78% 0.00% -102,234.53%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -7.12 -25.87 -16.44
Operating Cash Flow to Interest Expense		 -5.97 0.00 0.00 0.00 0.00 0.00 -9.45 -4.66 -16.36
Operating Cash Flow Less CapEx to Interest Expense		 -5.99 0.00 0.00 0.00 0.00 0.00 -9.59 -4.66 -16.38
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.06 0.42 0.66 0.01 0.02 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 2.32 3.02 6.95 1.97 2.02 0.78 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.03 0.55 68.29 1.38 2.55 0.88 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 157.24 120.91 52.50 185.05 181.09 469.32 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 157.24 120.91 52.50 185.05 181.09 469.32 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 -5.33 -29 15 13 11 -7.64 -8.55 -24
Invested Capital Turnover		 0.00 -1.13 -1.52 -8.35 0.06 0.15 0.37 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -5.33 -23 44 -2.09 -1.54 -19 -0.91 -15
Enterprise Value (EV)		 0.00 0.00 0.00 34 320 191 283 1,743 12,747
Market Capitalization		 0.00 0.00 0.00 98 387 263 417 1,829 13,160
Book Value per Share		 $0.00 $0.00 ($1.23) $1.07 $0.97 $0.85 $1.29 $0.11 $0.53
Tangible Book Value per Share		 $0.00 $0.00 ($1.56) $0.87 $0.80 $0.73 $1.27 $0.11 $0.52
Total Capital		 0.00 30 -4.54 79 79 83 641 178 389
Total Debt		 0.00 0.00 0.00 0.11 0.00 0.00 514 100 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 495 100 0.00
Net Debt		 0.00 -36 -29 -64 -66 -72 -134 -86 -413
Capital Expenditures (CapEx)		 0.10 0.11 0.68 0.16 0.42 0.31 0.62 -0.10 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -7.12 -9.95 2.12 1.37 -0.10 -11 -17 -31
Debt-free Net Working Capital (DFNWC)		 0.00 28 19 66 68 72 638 169 382
Net Working Capital (NWC)		 0.00 28 19 66 68 72 618 169 382
Net Nonoperating Expense (NNE)		 8.51 5.04 6.05 -4.42 15 28 28 188 63
Net Nonoperating Obligations (NNO)		 0.00 -36 -24 -64 -66 -72 -134 -86 -413
Total Depreciation and Amortization (D&A)		 0.05 0.06 0.42 1.51 2.00 2.46 1.26 -1.73 -2.49
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -235.78% -38.38% 3.72% 158.95% -5.64% -1,547.09% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 941.32% 72.19% 115.55% 7,881.86% 3,962.91% 90,453.90% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 941.32% 72.19% 115.37% 7,881.86% 3,962.91% 87,649.65% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.76) $0.00 ($0.41) ($0.99) ($0.31)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 73.56M 0.00 69.52M 0.00 193.34M 619.65M 718.54M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.76) $0.00 ($0.41) ($0.99) ($0.31)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 73.56M 0.00 69.52M 0.00 193.34M 619.65M 718.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 73.56M 0.00 82.92M 0.00 697.69M 701.70M 737.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -22 -23 7.48 -37 -60 -45 -427 -158
Normalized NOPAT Margin		 0.00% -729.51% -87.53% 13.09% -4,259.74% -3,335.00% -6,316.98% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -1,078.31% -131.57% 15.91% -6,152.33% -4,897.84% -10,849.65% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -7.07 0.00 0.00 0.00 0.00 0.00 -16.38 -37.04 -26.02
NOPAT to Interest Expense		 -4.95 0.00 0.00 0.00 0.00 0.00 -11.47 -25.93 -18.21
EBIT Less CapEx to Interest Expense		 -7.09 0.00 0.00 0.00 0.00 0.00 -16.52 -37.03 -26.03
NOPAT Less CapEx to Interest Expense		 -4.97 0.00 0.00 0.00 0.00 0.00 -11.61 -25.92 -18.23
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -20.79% 0.00% -7.08% 15.71% -0.09% -0.13% -0.14% -0.10% 0.00%

Quarterly Metrics and Ratios for Summit Therapeutics

This table displays calculated financial ratios and metrics derived from Summit Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -83.19% 0.00% -100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -9.65% 17.43% -2,417.23% -8.60% 3.01% -73.66% 91.91% -252.66% -195.01% -73.80%
EBIT Growth		 -9.75% 22.07% -2,347.77% 12.25% 0.55% -78.38% 91.98% -310.31% -164.50% -81.20%
NOPAT Growth		 13.07% 22.07% -2,324.20% -24.44% -20.97% -78.38% 92.11% -277.47% -184.88% -81.20%
Net Income Growth		 -9.11% 29.04% -2,434.82% 12.25% 0.55% -90.17% 91.98% -310.31% -164.50% -67.37%
EPS Growth		 50.00% -500.00% -853.33% 83.33% 70.00% 1,325.00% 95.80% -350.00% -166.67% -116.33%
Operating Cash Flow Growth		 63.70% 156.55% 30.89% -52.33% -74.13% -474.86% -129.49% -12.74% -103.38% -150.13%
Free Cash Flow Firm Growth		 94.60% 129.52% -3,335.69% 130.10% -222.71% -596.07% 92.87% -276.09% -346.41% -25.02%
Invested Capital Growth		 -48.86% -166.50% -170.35% -76.24% -96.15% -11.87% -51.33% -769.88% -5,814.29% -179.84%
Revenue Q/Q Growth		 -6.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -27.77% -1.36% -2,652.30% 96.76% -14.11% -81.48% -21.23% -41.33% 4.55% -6.91%
EBIT Q/Q Growth		 -27.51% 5.08% -2,571.93% 97.29% -44.51% -70.26% -18.89% -38.90% 6.84% -16.64%
NOPAT Q/Q Growth		 -33.47% -19.83% -2,546.21% 97.06% -29.75% -76.70% -17.06% -40.64% 2.08% -12.40%
Net Income Q/Q Growth		 -27.51% 10.08% -2,720.61% 97.29% -44.51% -71.93% -18.89% -38.90% 6.84% -8.80%
EPS Q/Q Growth		 16.67% 60.00% -3,475.00% 98.60% -50.00% 1,733.33% -112.24% -50.00% 11.11% 0.00%
Operating Cash Flow Q/Q Growth		 55.48% 160.68% -352.96% -122.93% 49.11% -30.62% -54.86% -9.52% 8.20% -60.65%
Free Cash Flow Firm Q/Q Growth		 91.06% 554.07% -7,316.71% 101.03% -195.84% -598.01% -3.66% 74.61% -142.98% -95.47%
Invested Capital Q/Q Growth		 -41.55% -167.78% -10.56% 154.26% -90.53% -2,070.05% -49.56% -140.20% 19.26% 3.52%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -9,396.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -7,700.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -9,720.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -9,720.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 118.87% 100.00% 100.00% 100.00% 76.58% 100.00% 100.00% 100.00% 82.07%
Interest Burden Percent		 100.00% 79.69% 100.00% 100.00% 100.00% 131.87% 100.00% 100.00% 100.00% 113.65%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -309.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -299.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 257.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -51.84% 0.00% 0.00% 0.00% -513.78% -601.85% -130.59% -102.77% -73.21% -94.90%
Cash Return on Invested Capital (CROIC)		 -262.33% 0.00% 0.00% -3,337.01% -6,912.72% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -65.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -65.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -51.84% 0.00% 0.00% 0.00% -513.78% -601.85% -130.59% -102.77% -73.21% -94.90%
Return on Equity Simple (ROE_SIMPLE)		 -65.03% 0.00% -449.32% -499.76% -601.32% 0.00% -262.44% -82.89% -44.91% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -14 -376 -11 -14 -25 -30 -42 -41 -46
NOPAT Margin		 -5,390.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -9.42% -4.87% -171.23% -4.98% -6.27% -10.18% -13.88% -10.95% -5.48% -6.12%
Return On Investment Capital (ROIC_SIMPLE)		 - -2.22% - - - -14.26% - - - -11.81%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 2,533.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 7,749.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 7,800.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -21 -20 -542 -15 -21 -36 -43 -60 -56 -66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -21 -542 -18 -20 -36 -44 -62 -59 -63
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.88 3.29 9.15 14.64 13.13 23.54 65.71 28.07 36.23 33.85
Price to Tangible Book Value (P/TBV)		 0.94 3.34 9.27 14.88 13.37 24.13 68.62 28.34 36.40 34.01
Price to Revenue (P/Rev)		 122.14 591.52 2,683.41 7,959.96 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 356.85 2,778.17 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 401.03 2,371.47 7,437.16 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 4.06 0.75 0.84 1.01 1.29 2.26 0.51 0.06 0.00
Long-Term Debt to Equity		 0.00 3.90 0.75 0.84 0.00 1.29 2.26 0.00 0.00 0.00
Financial Leverage		 -0.86 -0.98 -0.98 -0.86 -0.95 -1.08 -1.12 -1.08 -1.05 -1.07
Leverage Ratio		 1.21 3.70 1.88 1.95 1.61 4.24 2.43 1.84 1.34 1.37
Compound Leverage Factor		 1.21 2.95 1.88 1.95 1.61 5.60 2.43 1.84 1.34 1.56
Debt to Total Capital		 0.00% 80.24% 42.83% 45.54% 50.16% 56.28% 69.34% 33.89% 5.30% 0.00%
Short-Term Debt to Total Capital		 0.00% 3.08% 0.00% 0.00% 50.16% 0.00% 0.00% 33.89% 5.30% 0.00%
Long-Term Debt to Total Capital		 0.00% 77.16% 42.83% 45.54% 0.00% 56.28% 69.34% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 19.76% 57.17% 54.46% 49.84% 43.72% 30.66% 66.11% 94.70% 100.00%
Debt to EBITDA		 0.00 -7.26 -0.17 -0.17 -0.17 -0.16 -0.86 -0.62 -0.12 0.00
Net Debt to EBITDA		 0.00 1.90 0.24 0.19 0.17 0.14 0.49 1.40 2.32 0.00
Long-Term Debt to EBITDA		 0.00 -6.98 -0.17 -0.17 0.00 -0.16 -0.86 0.00 0.00 0.00
Debt to NOPAT		 0.00 -10.19 -0.24 -0.24 -0.24 -0.23 -1.24 -0.90 -0.18 0.00
Net Debt to NOPAT		 0.00 2.66 0.35 0.28 0.24 0.20 0.71 2.03 3.36 0.00
Long-Term Debt to NOPAT		 0.00 -9.80 -0.24 -0.24 0.00 -0.23 -1.24 0.00 0.00 0.00
Altman Z-Score		 0.42 0.68 -4.96 4.29 0.62 2.32 5.08 17.97 144.07 165.32
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 8.22 16.93 14.22 19.07 1.80 9.30 6.97 2.35 8.31 10.15
Quick Ratio		 7.32 9.00 13.87 18.02 1.75 9.13 6.68 2.32 8.25 9.88
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.09 4.93 -356 3.65 -3.50 -24 -25 -6.43 -16 -31
Operating Cash Flow to CapEx		 0.00% 0.00% -24,775.47% -146,365.00% -28,107.55% -972,950.00% -753,350.00% -52,384.13% -52,236.21% -347,664.29%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.79 0.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.21 0.88 0.66 0.33 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 463.89 469.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 463.89 469.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 11 -7.64 -8.45 4.59 0.43 -8.55 -13 -31 -25 -24
Invested Capital Turnover		 0.06 0.37 0.26 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -11 -19 -20 -15 -11 -0.91 -4.34 -35 -25 -15
Enterprise Value (EV)		 -5.21 283 1,079 1,636 1,206 1,743 2,848 5,250 15,405 12,747
Market Capitalization		 117 417 1,221 1,751 1,305 1,829 2,905 5,475 15,867 13,160
Book Value per Share		 $1.36 $1.29 $0.19 $0.17 $0.14 $0.11 $0.06 $0.28 $0.60 $0.53
Tangible Book Value per Share		 $1.26 $1.27 $0.19 $0.17 $0.14 $0.11 $0.06 $0.28 $0.60 $0.52
Total Capital		 133 641 233 220 199 178 144 295 462 389
Total Debt		 0.00 514 100 100 100 100 100 100 25 0.00
Total Long-Term Debt		 0.00 495 100 100 0.00 100 100 0.00 0.00 0.00
Net Debt		 -122 -134 -142 -115 -99 -86 -57 -226 -463 -413
Capital Expenditures (CapEx)		 -0.02 -0.01 0.05 0.02 0.05 0.00 0.00 0.06 0.06 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.53 -11 -11 0.56 -7.74 -17 -17 -37 -31 -31
Debt-free Net Working Capital (DFNWC)		 120 638 231 216 191 169 140 289 456 382
Net Working Capital (NWC)		 120 618 231 216 91 169 140 189 431 382
Net Nonoperating Expense (NNE)		 9.53 5.02 166 3.66 6.92 11 14 19 15 15
Net Nonoperating Obligations (NNO)		 -122 -134 -142 -115 -99 -86 -57 -226 -463 -413
Total Depreciation and Amortization (D&A)		 0.71 -0.66 0.09 -2.86 1.22 -0.18 -0.38 -1.59 -2.90 2.37
Debt-free, Cash-free Net Working Capital to Revenue		 -160.46% -1,547.09% -2,494.07% 252.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 12,598.01% 90,453.90% 50,677.80% 97,986.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 12,598.01% 87,649.65% 50,677.80% 97,986.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.14) ($0.04) ($1.43) ($0.02) ($0.03) $0.49 ($0.06) ($0.09) ($0.08) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 148.58M 193.34M 378.16M 697.69M 697.74M 619.65M 701.79M 707.90M 726.66M 718.54M
Adjusted Diluted Earnings per Share		 ($0.14) ($0.04) ($1.43) ($0.02) ($0.03) $0.49 ($0.06) ($0.09) ($0.08) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 148.58M 193.34M 378.16M 697.69M 697.74M 619.65M 701.79M 707.90M 726.66M 718.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 201.32M 697.69M 697.69M 697.69M 700.84M 701.70M 701.98M 724.54M 737.45M 737.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -14 -376 -11 -14 -25 -30 -42 -41 -46
Normalized NOPAT Margin		 -5,390.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -9,720.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.08% -0.14% -0.11% -0.12% 0.00% -0.10% -0.07% 0.00% 0.00% 0.00%

Frequently Asked Questions About Summit Therapeutics' Financials

When does Summit Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Summit Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Summit Therapeutics' net income changed over the last 8 years?

Summit Therapeutics' net income appears to be on an upward trend, with a most recent value of -$221.32 million in 2024, rising from -$29.06 million in 2016. The previous period was -$614.93 million in 2023.

What is Summit Therapeutics's operating income?
Summit Therapeutics's total operating income in 2024 was -$226.00 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $226.00 million
How has Summit Therapeutics revenue changed over the last 8 years?

Over the last 8 years, Summit Therapeutics' total revenue changed from $0.00 in 2016 to $0.00 in 2024, a change of 0.0%.

How much debt does Summit Therapeutics have?

Summit Therapeutics' total liabilities were at $46.81 million at the end of 2024, a 62.6% decrease from 2023, and a 10.0% decrease since 2017.

How much cash does Summit Therapeutics have?

In the past 7 years, Summit Therapeutics' cash and equivalents has ranged from $28.67 million in 2018 to $348.61 million in 2022, and is currently $104.86 million as of their latest financial filing in 2024.

How has Summit Therapeutics' book value per share changed over the last 8 years?

Over the last 8 years, Summit Therapeutics' book value per share changed from 0.00 in 2016 to 0.53 in 2024, a change of 52.7%.

Remove Ads

Related Companies

This page (NASDAQ:SMMT) was last updated on 4/14/2025 by MarketBeat.com Staff
From Our Partners
The biggest story CNBC isn't talking about (yet)
This Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...
Stansberry Research | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
BITCOIN
Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....
Awesomely, LLC | Sponsored
Elon Musk is helping print “new gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...
True Market Insiders | Sponsored
Catastrophic
The losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.
InvestorPlace | Sponsored
Trump’s betrayal exposed
Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...
Porter & Company | Sponsored
Musk’s AI Masterplan – Our #1 AI Stock to Buy Now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...
Behind the Markets | Sponsored
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored